KDR and cancer: The objectives of this study were to develop a robust VEGFR2 IHC assay using a commercially available anti-VEGFR2 monoclonal antibody (clone 55B11) to demonstrate selective and specific endothelial cell and tumor cell staining on various human cancer tissues, and to evaluate its analytical performance and clinical utility on an independent cohort of NSCLC tissues.